Survival analyses showed that high expression of BZW1 and BZW2 were significantly associated with short OS for PAAD patients (p = 0.040 for BZW1 probe 11757867_s_at, p = 0.046 for BZW1 probe 11744775_x_at and p = 0.030 for BZW2 probe 11747677_a_at) (Figures 4D–F). This evidence concerns the gene BZW1 and pancreatic adenocarcinoma.